Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19
Chippenham, UK and London, UK – 6 May 2021: Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, today announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the treatment of COVID-19.
Inspira’s research focuses on proprietary IPX formulations, which are based on processed and purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus
in vitro. The IPX technology platform has additional potential applications in other lung infections and treatment of biofilms associated with respiratory disease.